BioSpace News Archive

Opiant Pharmaceuticals, Inc. (“Opiant”) (Nasdaq: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that its Chief Executive Officer, Dr. Roger Crystal, will participate in a fireside chat at the 32nd Annual Oppenheimer Healthcare Conference taking place virtually March 15 - March 17.

NeuroPace, Inc., a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, reported financial results for the fourth quarter and full year ended December 31, 2021.

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced its financial results for the fourth quarter and full year 2021 and provided an overview of recent business highlights.

Homology Medicines, Inc., a genetic medicines company, announced the successful closing of the deal with Oxford Biomedica plc to establish an Adeno-Associated Virus Manufacturing and Innovation Business.

Evoke Pharma, Inc., a specialty pharmaceutical company focused primarily on treatments for gastrointestinal diseases, announced that together with the research team at H.C. Wainwright & Co., it will host a virtual key opinion leader fireside chat on March 16, 2022, at 10:00 a.m. ET.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to ALLO-316, the Company’s first AlloCAR T solid tumor clinical candidate for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC).

Mustang Bio, Inc. announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in three virtual investor conferences in March 2022.

Nuvectis Pharma, Inc. (NASDAQ: NVCT), (“Nuvectis” or the “Company”) a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, today announced that an abstract related to NXP800 has been selected for an oral presentation and an abstract related to NXP900 has been selected for a poster presentation at the upcoming 2022 American Association for Cancer Research Meeting.

Relmada Therapeutics, Inc. announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in fireside chats at Needham & Company’s 1st Annual Neuroscience Forum and Oppenheimer’s 32nd Annual Healthcare Conference, taking place March 16th, 2022 at 9:30am ET and March 17th, 2022 at 1:20pm ET, respectively.

Emerging Technology Insider announced a new TechTalks video featuring an interview with Richard T. Schumacher, CEO and Founder of Pressure BioSciences, Inc..